4basebio Expands Manufacturing Capacity with New 26,500 Square Foot Cambridge Facility to Meet Growing Synthetic DNA Demand
Key Insights
4basebio (search) PLC announces a significant expansion with a new innovation hub and manufacturing facility in Cambridge, UK, featuring 26,500 square feet of purpose-built space including 15 specialized laboratories.
The facility will support growing demand for high-quality synthetic DNA (search) manufacturing for gene and cell therapies (search), mRNA vaccines (search), genome editing, and DNA vaccines (search) as next-generation therapeutics advance.
The company's proprietary enzymatic DNA synthesis platform produces GMP-grade synthetic DNA (search) with superior purity, safety, and scalability compared to traditional plasmid-based systems.
4basebio (search) PLC, a specialist in synthetic DNA (search) manufacturing for next-generation therapeutics, announced a major expansion with the lease of a new innovation hub and manufacturing facility in Cambridge, UK. The 26,500 square foot facility at 31-35 Saxon Way, Bar Hill, will support the growing demand for research and high-quality grade manufacturing of synthetic DNA for gene and cell therapies (search), mRNA vaccines (search), genome editing, and DNA vaccines (search).
Facility Specifications and Infrastructure
The new facility will provide approximately 26,500 square feet of purpose-built space, including 7,500 square feet of specialized laboratory space with 15 individual labs equipped with advanced biosafety cabinets, fume hoods, and state-of-the-art air handling systems, plus cold room and dedicated IT infrastructure. The facility will also house modern office space for staff and includes an additional 7,500 square feet allocated for future expansion, with 2,000 square feet of additional lab space already in the design phase.
The build-out and construction is being delivered by Zero Workspace (search), a specialist in the design and delivery of complex laboratory and technical workspaces for life sciences and innovation-led occupiers across the UK. 4basebio (search) is expected to move into the facility late summer 2026, once the building has been developed.
Market Demand and Strategic Positioning
Demand for next-generation therapeutics is increasing, driving biotech and pharmaceutical companies to source high-quality synthetic DNA (search) from trusted providers. DNA is critical for mRNA vaccines (search) and cell and gene therapies (search), particularly as personalized medicine advances. Compared with plasmid DNA, synthetic DNA offers advantages in purity, safety and scalability. As development pipelines mature, demand for research and high-quality DNA manufacturing is expected to grow, and this facility enables 4basebio (search) to meet that demand.
Leadership Commentary
Dr Amy Walker, Chief Executive Officer of 4basebio (search), said: "Our customers rely on us to provide high quality synthetic DNA (search) to meet demand for next generation genomic therapies including RNA therapeutics, cell and gene therapy, and vaccine development. This new facility strengthens our ability to support our customers as they advance their drug development through clinical phases. We're proud to be part of Cambridge's world-class life sciences ecosystem, and deliver on our commitment to becoming the partner of choice for our partners."
Barnaby Clark, Director at Zero Workspace (search), added: "We're proud to be supporting 4basebio (search) on the delivery of this new facility that will allow them to continue to perform their pioneering work to support the next-generation of medicine. The project builds on our growing track record in designing and delivering high-specification laboratory environments, enabling innovative companies to scale and advance cutting-edge scientific work."
Technology Platform
4basebio (search) operates through its proprietary enzymatic DNA synthesis platform, which produces GMP-grade synthetic DNA (search) and mRNA with superior speed, purity, and scalability, overcoming the limitations of plasmid-based systems. The company offers application-specific DNA constructs tailored to the diverse needs of gene therapies (search), genome editing, mRNA production, and DNA vaccines (search), helping partners accelerate proof-of-concept studies and reach clinical milestones more efficiently while maintaining the highest standards of safety and quality.
The facility is being leased from Peterhouse (search), the University of Cambridge's oldest college, which has a long tradition of supporting academic excellence and scientific innovation. The expansion represents a significant investment in the company's manufacturing capabilities as it positions itself to serve the growing market for synthetic DNA (search) in advanced therapeutics development.